Mind Medicine (MindMed) Inc.

NasdaqGS MNMD

Mind Medicine (MindMed) Inc. Price to Earnings Ratio (P/E) on December 19, 2024: -5.26

Mind Medicine (MindMed) Inc. Price to Earnings Ratio (P/E) is -5.26 on December 19, 2024, a -198.42% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Mind Medicine (MindMed) Inc. 52-week high Price to Earnings Ratio (P/E) is -1.63 on January 24, 2024, which is 69.10% above the current Price to Earnings Ratio (P/E).
Mind Medicine (MindMed) Inc. 52-week low Price to Earnings Ratio (P/E) is -6.97 on July 25, 2024, which is -32.55% below the current Price to Earnings Ratio (P/E).
Mind Medicine (MindMed) Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -4.52.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqGS: MNMD

Mind Medicine (MindMed) Inc.

CEO	Mr. Robert Barrow
IPO Date	Nov. 15, 2016
Location	Canada
Headquarters	1055 West Hastings Street
Employees	57
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

Key trends

Past 5 years